EVIDERA, INC.

Evidera, Inc. specializes in health economics, outcomes research, and real-world evidence generation to support regulatory, reimbursement, and market access decisions for pharmaceutical, biotech, and medical device clients engaged with federal health programs. The company provides advanced analytical services including statistical modeling, health policy analysis, cost-effectiveness modeling, and patient-reported outcome instrument development, leveraging epidemiological data, claims databases, and electronic health records to generate actionable insights for public health decision-makers. Their technical expertise spans pharmacoeconomic evaluation frameworks, survival analysis, Bayesian modeling, and health technology assessment methodologies aligned with guidelines from ICER, NICE, and CMS. While award history is not available to confirm specific agency engagements, Evidera’s domain focus suggests alignment with federal health and regulatory entities such as CMS, FDA, and NIH, where real-world evidence and economic modeling are increasingly critical to policy and coverage determinations. The firm’s work supports evidence-based decision-making in areas including orphan drug valuation, comparative effectiveness research, and value-based payment design. Evidera operates under NAICS 541690, which encompasses other scientific and technical consulting services, reflecting its role as a specialized advisor in health outcomes and economic analysis rather than a general IT or engineering contractor. The company is positioned at the intersection of clinical research and public health policy, serving clients who require rigorous, transparent, and reproducible evidence to navigate complex regulatory and reimbursement landscapes. Evidera, Inc. is a small business structured as a 2L entity headquartered in Bethesda, Maryland, with no federal certifications on record. Its geographic presence is centered in the Washington, D.C. metro region, enabling proximity to federal health agencies and policy stakeholders. The firm’s market positioning is defined by its deep technical specialization in health economics and outcomes research, serving a niche but mission-critical segment of the federal health ecosystem.